Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab

NCT ID: NCT04727164

Last Updated: 2021-01-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-28
• Study Completion Date: 2023-11-30

Brief Summary

HBM4003 in combination with Toripalimab. The expected duration of treatment for each subject will vary according to the number of cycles completed; the number of cycles will depend on whether the subject benefits from the treatment. The study consists of a 4-week screening period, a 21-day treatment cycle (repeatable, depending on the presence/absence of clinical benefit), EOT visit after discontinuation of treatment, and 2 follow-up visits 28 days (± 2 days) and 84 days (± 5 days) after the last study medication.

Detailed Description

An open-label Phase 1 study to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 combined with toripalimab in patients with advanced melanoma and other solid tumors.

The study is composed of two part, part 1 will be approximately 31subjects and Part 2 will be approximately 30 subjects.

Conditions

Solid Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HBM4003+Toripalimap

HBM4003 combined with toripalimab in patients with advanced melanoma and other solid tumors

Group Type: EXPERIMENTAL

HBM4003 and Triprilimab

Intervention Type: DRUG

Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.

Interventions

HBM4003 and Triprilimab

Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.

Intervention Type: DRUG

Other Intervention Names

HBM4003

Eligibility Criteria

Inclusion Criteria

1. Males or females aged ≥ 18 years at the time of signing the informed consent form. For Part 1 of this study, the subjects should be ≤ 75 years of age.

2. For Part 1 of the study, patients histopathologically diagnosed with advanced or recurrent solid tumors

3. For Part 2 of the study, patients with locally advanced or metastatic melanoma who had been pathologically confirmed and could not be surgically removed were enrolled.

4. Subjects must be able to provide fresh or archived tumor tissues .

5. Patients whose estimated survival time is more than 3 months.

6. Patients with at least one measurable lesion at baseline according to RECIST (Version 1.1).

7. Patients with Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1.

8. Patients whose organ function must meet the study requirements:

9. Every woman or man with potential fertility needs to use an effective contraceptive method.

Exclusion Criteria

1. Patients who are simultaneously participating in another clinical study, unless the study is an observational (non-interventional) clinical study or the patient is already in the survival follow-up period of the interventional study.

2. Patients with a history of severe allergic diseases, a history of severe drug allergies, and known or suspected allergy to macromolecular protein preparations or HBM4003 excipients or toripalimab excipients.

3. Previous and concomitant drugs or treatments to be excluded like CTLA4, PD-1,PD-L1.

4. Insufficient recovery from previous treatments:

5. Diseases that may affect the efficacy and safety of the investigational product.

6. A history of other malignant diseases within 5 years before the first dose.

7. Symptomatic, active, or urgent treatment-requiring central nervous system (CNS) metastasis with imaging evidence (based on CT or MRI assessment).

8. Subjects with pleural effusion, pericardial effusion, or ascites

9. Subjects who the investigator believes may have other factors that will affect the efficacy or safety evaluation of this study (e.g., mental disorders, alcoholism, drug use, etc.).

10. Women who are pregnant or breastfeeding, or who plan to become pregnant during the study period and within 3 months after the last administration of the investigational product.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Harbour BioMed (Guangzhou) Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

JUN GUO, DOCTOR

Role: PRINCIPAL_INVESTIGATOR

Peking University Cancer Hospital & Institute

Central Contacts

Wangnan ZHOU, Master

Role: CONTACT

Phone: +13810905733

Email: wangnan.zhou@harbourbiomed.com

Peter ZHAO

Role: CONTACT

Phone: +8617601647910

Email: peter.zhao@harbourbiomed.com

References

Tang B, Chen Y, Jiang Y, Fang M, Gao Q, Ren X, Yao L, Huang G, Chen J, Zhang X, Li R, Zhao S, Gao M, Luo R, Qi M, Li F, Zheng F, Lee M, Tao X, Duan R, Guo J, Chi Z, Cui C. Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial. J Immunother Cancer. 2024 Oct 4;12(10):e009662. doi: 10.1136/jitc-2024-009662.

Reference Type: DERIVED

PMID: 39366752 (View on PubMed)

Other Identifiers

4003.2

Identifier Type: -

Identifier Source: org_study_id